Commentary The Biden administration took action this month against 34 Chinese entities with close ties to the People’s Liberation Army (PLA). The 12 Chinese research institutes and 22 Chinese tech firms in question have a history of weaponizing biotechnology and enabling human rights abuses in Xinjiang. The Biden administration, clearly concerned by the threats posed, chose to impose a whole host of trade and investment restrictions on the highly-questionable entities. According to Commerce Secretary Gina Raimondo, although “the scientific pursuit of biotechnology and medical innovation can save lives,” the Chinese Communist Party (CCP) instead chooses “to use these technologies to pursue control over its people and its repression of members of ethnic and religious minority groups. We cannot allow U.S. commodities, technologies, and software that support medical science and biotechnical innovation to be diverted toward uses contrary to U.S. national security.” Most worryingly of all, many of the aforementioned institutes …